The effects of terbium on the accumulation of cisplatin in human ovarian cancer cells  by Canada, Robert G. et al.
ELSEVIER Biochimica et Biophysica Acta 1267 (1995) 25-30 
BB 
Biochi~ic~a et Biophysica A~ta 
The effects of terbium on the accumulation of cisplatin in human ovarian 
cancer cells 
Robert G. Canada a, * ,  Paul A. Andrews b, Kelly M. Mack a, Adnan Haider c 
a Laboratory of Biophysical Cytochemistry, Department ofPhysiology and Biophysics, Howard University College of Medicine, Washington, D.C. 20059, 
USA 
b Department of Pharmacology, Georgetown University, Washington, D.C. 20007, USA 
c Depatgment of Mathematics, Howard University School of LiberalArts, Washington, D.C. 20059, USA 
Received 26 August 1994; revised 25 January 1995; accepted 27 January 1995 
Abstract 
In this investigation, we report a relationship between the terbium (Tb 3 +) binding protein and the accumulation f cisplatin in human 
ovarian cancer cells. The number of Tb 3÷ binding sites in cisplatin-resistant C13 * cells is significantly greater by 79% than those in 
cisplatin-sensitive 2008 cells. Exposure to Tb 3÷ also increased the cellular accumulation of cisplatin. The accumulation of cisplatin as a 
function of the Tb 3+ concentration in the C13 * cells (0.85%//xM Tb 3+) was significantly greater than the accumulation of cisplatin in 
2008 cells with respect to Tb -~ ÷ (0.46%//.tM Tb 3 ÷ ). The number of Tb 3 + binding sites in revertant RH4 cells was similar to that in 2008 
cells. The RH4 cells were less sensitive to the stimulatory effects of Tb 3+ than the C13" cells. Our results show that the Tb 3+ binding 
protein correlates with cisplatin resistance, and the receptor binding of Tb 3 + increases the accumulation f cisplatin in cisplatin-resistant 
cells. 
1. Introduction 
The development of cisplatin resistance by the cancer 
cell is one of the major problems in treating patients with 
cisplatin chemotherapy [ 1,2]. The reduced accumulation of 
cisplatin has emerged as a prominent feature in many 
cisplatin-resistant cell lines [ 1,2]. In cisplatin-resistant C 13 * 
human ovarian cancer cells, the accumulation of cisplatin 
is approximately 50% less than that in the parent 
cisplatin-sensitive 2008 cells. Andrews and co-workers 
have established that the number of Na+,K+-ATPase 
molecules in resistant C13'  cells is less than the number 
of Na+,K+-ATPase molecules in sensitive 2008 cells [3]. 
The inhibition of Na+,K%ATPase activity by ouabain, 
ATP depletion or K÷-free medium decreased the cellular 
accumulation of cisplatin. The accumulation of cisplatin 
was suggested to be dependent on the Na + concentration 
gradient [3]. A 200kDa gl:¢coprotein has been reported in 
the plasma membrane of cisplatin-resistant mouse lym- 
phoma cells that inversely correlated with the reduced 
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accumulation of cisplatin in these cells [2]. In human 
squamous carcinoma cells, the reduced membrane content 
of a 46kDa protein, SQM1, has been associated with the 
defective cellular accumulation of cisplatin as well as 
methotrexate [2]. Despite these leads, the biochemical 
mechanism underlying decreased cisplatin accumulation 
has not been established in any cell line. 
Terbium (Tb3+), a rare-earth lanthanide metal, is a 
phosphorescent probe of Ca 2 ÷ binding sites [5,6]. A spe- 
cific Tb 3÷ binding protein has been identified in the 
plasma membrane of tumorigenic ells [7-10]. This Tb 3+ 
binding protein has been suggested to be involved in the 
transport of cisplatin across the plasma membrane [8]. 
Recently, we have shown that hyperthermia can increase 
the affinity of cisplatin for the Tb 3+ binding protein in 
human breast tumor cells [11]. However, further work to 
uncover the rate of increase and the behavior of such 
increasing effect may be considered for future work. Hy- 
perthermia has been used in vitro as an effective agent 
against cisplatin resistance [1]. Hyperthermia was found to 
enhance the accumulation and cytotoxicity of cisplatin in 
both resistant and sensitive Chinese hamster ovary cells 
[12], in sensitive Chinese hamster fibroblast and resistant 
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hamster kidney cells [13] and in human esophageal cancer 
cells [14]. In the present study, we report hat the defective 
accumulation of cisplatin in ovarian cancer cells can be 
overcome by the presence of Tb 3÷, and that the Tb 3÷ 
binding protein may be associated with cisplatin resistance. 
due to light scattering and interferences due to the intrinsic 
fluorescence of the cells. All measurements were made on 
3-ml samples in 1 × l-cm quartz cuvettes at 37 ° C. 
2.4. Cisplatin accumulation 
2. Materials and methods 
2.1. Chemicals 
Cisplatin (clinical formulation) was obtained from Bris- 
tol-Myers Oncology Division (Syracuse, NY). Terbium(Ill) 
trichloride hexahydrate was purchased from Aldrich 
(Milwaukee, WI, USA). Tb 3+ stock solutions were made 
with high-quality, 18 M O-cm, water; the water was pro- 
cessed by reverse osmosis and deionization. All chemicals 
were of analytical quality and were used as received. 
2.2. Cell cultures 
The parent cisplatin-sensitive 2008 cell line was estab- 
lished from a patient with serous cystadenocarcinoma of 
the ovary [15]. The cisplatin-resistant C13" subline was 
generated from the 2008 cells as described [4]. Revertant 
RH4 cells were selected from the C13 * subline by expo- 
sure to 5 ~g/ml  rhodamine 123 [16]. The cells were 
grown as monolayers in RPMI-1640 medium supple- 
mented with 10% fetal bovine serum and without antibi- 
otics. Cultures were maintained at 37°C in a humidified 
atmosphere of 5% CO 2 and 95% air. 
2.3. Phosphorescence measurements 
Confluent cell cultures in 75-cm 2 flasks were harvested 
with trypsin-EDTA (0.5 g porcine trypsin in 0.2 g EDTA. 
4 Na/liter Hanks' Balanced Salt Solution), washed twice 
by centrifugation, and resuspended in a Hepes-buffered 
saline (HBS). The HBS (osmolarity = 314 mOsm) con- 
tained 145 mM NaC1, 5 mM KC1, 1 mM MgC1 e • 6H20, 1 
mM CaC12 • 6H20 and 6 mM o-glucose in 10 mM Hepes 
(pH 7.2). Cells were counted using a hemacytometer. 
Time-resolved intensities were measured on a Spex 
Industries Fluorolog-2 Model F212I Spectrofluorometer, 
equipped with a phosphorimeter accessory. The cell sus- 
pensions were excited with a pulsed xenon lamp (7 Watts), 
having a pulse width at 1/3 peak intensity of less than 15 
/xs. Each data point was the accumulation of 100 flashes at 
a pulse rate of 10/s. The excitation wavelength and 
entrance slit were at 280 and 5 nm, respectively. The exit 
slit and emission wavelength were at 10 and 543 nm, 
respectively. A 450 nm longwave pass filter was placed 
between the exit slit and emission monochromator. The 
gating of the sample photomultiplier was delayed by 50/xs 
after the flash of the xenon lamp; the duration of the 
sample window was set at 100 /zs. This eliminated error 
The cellular accumulation of cisplatin was determined, 
as previously described [17]. Cells were seeded into 60-mm 
culture dishes and grown to confluence. The medium was 
replaced with 3 ml of 100 p~M cisplatin with various 
concentrations of Tb 3+ in HBS. The cells were incubated 
for 1 h at 37 ° C, in the ambient atmosphere. Afterward, the 
medium was aspirated, and the cultures washed four times 
with ice-cold phosphate-buffered saline. Cells were scraped 
thoroughly from the bottom surface of the dish, in the 
presence of 1 ml of 0.1% Triton X-100/0.1 N HC1. The 
cell suspension was transferred to snap-cap tubes and 
frozen. Later, the samples were thawed, and sonicated for 
15 s at a power output of approximately 7 Watts. Twenty 
/zl of the cell lysate were removed for protein determina- 
tion. Twenty /zl of the cell lysate were analyzed for 
platinum via electrothermal atomic absorption spectropho- 
tometry (Perkin-Elmer, Norwalk, CT) as described [16]. 
2.5. Data analysis 
Equilibrium binding constants, i.e., the change in maxi- 
mum intensity (A/ma x ) and the apparent dissociation con- 
stant (Kd), were obtained by using a nonlinear egression 
analysis program. Values of the reported data are the 
mean + the standard error of the mean (S.E.M.). In the 
binding studies, each data point was the mean of nine 
separate xperiments. In the accumulation studies, each 
data point was the mean of 3-5 experiments. Statistical 
analysis used Student's unpaired t-test to test if a signifi- 
cant difference exists. A one-way analysis of variance 
(ANOVA) was used to evaluate the effects of Tb 3÷ con- 
centration on the cellular accumulation of cisplatin. A 
two-way ANOVA was used to compare the effects of both 
Tb 3+ concentration a d cell line on the cellular accumula- 
tion of cisplatin. Levels of significance have been defined 
for each case. 
3. Results 
Fig. 1 shows the equilibrium binding of Tb 3÷ to human 
ovarian cancer cells. The intensity of the Tb3+/cell com- 
plex increased hyperbolically as a function of the Tb 3÷ 
concentration. The intensity at saturation (A/ma x ) is pro- 
portional to the maximum amount of Tb 3+ bound per cell. 
A/ma x was 221.1 + 18.3 for the Tb3+//C13 * complex, 
123.7 + 10.4 for the Tb3+/2008 complex and 116.0 + 18.5 
for the Tb3+/RH4 complex. This indicates that the num- 
ber of Tb 3+ binding sites on a cisplatin-resistant C13 * cell 
is significantly greater by 79% than the number of Tb 3+ 
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Fig. 1. Binding of Tb 3+ to C13 * (cisplatin-resistant), 2008 (cisplatin- 
sensitive) and RH4 (cisplatin-revertant) human ovarian cancer cells. The 
normalized change in intensity, i.e., (A) Intensity, of the Th3+/cell 
complex was plotted as a function of the Tb 3+ concentration. The (A) 
Intensity is equal to the value of the intensity of Tb 3+ with ceils minus 
the value of the intensity of Tb 3+ without cells, normalized to the 
maximum intensity change of the Tb3+/2008 complex at 97/xM Tb 3+. 
Inset: Eadie-Hofstee plot of binding of Tb 3+ to C13', 2008 and RH4 
cells. Abscissa: (A) Intensity divided by its corresponding Th3+ concen- 
tration. Ordinate: (A) Intensity. C13 * (O), 2008 (O) and RH4 ( • ) cells 
in suspension at50,000 cells/ml were titrated with Tb 3+, while under 
gentle stirring. The concentration f Tb 3+ in suspension ranged from 2 
to 97/xM. Intensities were measured 10 s after each aliquot (2-10/xl) of 
reagent. The total change in sample volume did not exceed 5%. Each 
value defines the mean and the S.E.M. of nine experiments. 
binding sites on a cisplatin-sensitive 2008 cell (P  < 0.01). 
Further, the number of Tb 3+ binding sites in the plasma 
membrane of a revertant RH4 cell is equivalent to that of a 
cisplatin-sensitive 2008 cell (P  > 0.1). The binding affin- 
ity of Tb 3+ was the same for each cell line (as indicated 
by parallel slopes in the inset of Fig. 1) (P  > 0.7). Kd'S for 
the Tb3+/C13 *, Tb3+/2008 and Tb3+/RH4 complexes 
were 50.8 + 6.9/~M, 41.4 _ 8.2 /xM and 49.0 + 9.5 /zM, 
respectively. These results show that an elevated produc- 
tion of the Tb 3+ binding protein (sites) may be associated 
with cisplatin resistance. 
The defective accumulation of cisplatin is a character- 
istic feature of many cisplatin-resistant cell lines. As exhib- 
ited in Fig. 2 and Table 1, the accumulation of cisplatin in 
HBS was 27.4 ___ 2.3% less in C13" cells than in sensitive 
2008 cells (P  < 0.01). Further, the accumulation of cis- 
platin in the RH4 cells was 38.6 + 7.5% less than in the 
2008 cells (P  < 0.01). There was no significant difference 
between the accumulation of cisplatin in RH4 and C13 * 
cells (P  > 0.1). Despite the substantial loss of resistance, 
the defective accumulatio~L of cisplatin was conserved in 
the revertant RH4 cell line, as previously reported [16]. 
When the cells were treated for 1 h with I00 /~M 
cisplatin, in the presence of various concentrations of 
Tb 3+, the cellular accumulation of cisplatin linearly in- 
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Fig. 2. Accumulation of cisplatin in 2008 (cisplatin-sensitive), C13" 
(cisplatin-resistant) and RH4 (cisplatin-revertant) cells, without Tb 3+. 
Cells were incubated for 1 h with 100 /xM cisplatin. The right-hand 
ordinate represents the cellular accumulation of cisplatin in pmol /mg 
protein that corresponds to the left-hand ordinate representing the percent- 
age of control. Where 100% of the control accumulation corresponds to 
803 pmol /mg protein. Bars show the means and the S.E.M. of five 
experiments. 
creased as a function of the Tb 3+ concentration (Fig. 3). A 
one-way ANOVA revealed that, for cisplatin-resistant 
C13 * cells, the accumulation of cisplatin increased signifi- 
cantly with the Tb 3+ concentration (P  < 0.04) (Fig. 3A). 
This implies that the accumulation of cisplatin in a cis- 
platin-resistant cell is dependent on the amount of Tb 3- in 
its environment. In the C13" cells, the change in the 
accumulation of cisplatin with respect o the Tb 3+ concen- 
tration, i.e., the slope of the line (m = 0.85), was 1.8-fold 
greater than that in the 2008 cells (m = 0.46). The accu- 
mulation of cisplatin in cisplatin-resistant C13 * cells is 
more responsive to Tb 3+ than the accumulation of cis- 
platin in cisplatin-sensitive 2008 cells. Especially, since 
Tb 3+ concentrations below 50 /xM did not significantly 
increase the accumulation of cisplatin in 2008 cells (P > 
0.2). The greater susceptibility of the C13 * cells to the 
stimulatory effects of Tb 3÷ was confirmed by a two-way 
ANOVA; a significant group difference was revealed be- 
tween the cisplatin-resistant C13" and cisplatin-sensitive 
2008 cell lines (P  < 0.01). Table 1 demonstrates that, at 
100 /xM Tb 3+, the defective accumulation of cisplatin in 
C13 * cells was approximately 2% less than the accumula- 
tion of cisplatin in 2008 cells. Collectively, these results 
suggest hat Tb 3+ can negate the defective accumulation 
Table 1 
Defective accumulation a of cisplatin in C13" (cisplatin-resistant) and 
RH4 (cisplatin-revertant) cells, at various Tb 3÷ concentrations 
Tb 3+ concentration (/xM) 
Cell line 0.0 10 100 
C13" 27.4±2.3% b 16.6+5.3% 2.1 ± 11.9% 
RH4 38.6±7.5% 40.1±6.3% 24.2±15.4% 
a Relative to 2008 cells. 
b Mean + SEM, n = 5. 
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Fig. 3. Enhancement of the cellular accumulation of cisplatin, as function 
of the Tb 3+ concentration. The percentage of increase in cisplatin 
accumulation, i.e., (A%)cisplatin accumulation, was calculated by sub- 
tracting the accumulation of cisplatin without Tb 3+ from the accumula- 
tion of cisplatin with Tb 3+, dividing the difference by the accumulation 
of cisplatin without Tb 3+ and multiplying the quotient by 100%. The 
2008 (C)), C13 * (0 )  and RH4 (A) cells were incubated for 1 h with 100 
/xM cisplatin, in the presence of either 0, 10, 20, 30, 40, 50, 75 or 100 
/xM of Tb 3+. Each value defines the mean and the S.E.M. of three to five 
experiments. 
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Fig. 4. Defective accumulation of cisplatin in resistant C13 * and rever- 
tant RH4 cells, as function of the Tb 3+ concentration. The defective 
accumulation of cisplatin, i.e., % defect, was calculated at each Tb 3+ 
concentration, bysubtracting the accumulation ofcisplatin in the C13 * or 
RH4 cells from the accumulation of cisplatin in the 2008 cells, dividing 
the difference by the accumulation of cisplatin in the 2008 cells, and 
multiplying the quotient by 100%. The C13" (©) and RH4 (0 )  cells 
were incubated for 1 h with 100/xM cisplatin, in the presence of either 0, 
10, 20, 30, 40, 50, 75 or 100 /zM of Tb 3+. Each values defines the mean 
and the S.E.M. of three to five experiments. 
of cisplatin in cisplatin-resistant cells via stimulating the 
cellular accumulation of cisplatin. 
In revertant RH4 cells, the accumulation of cisplatin 
increased significantly with the Tb 3÷ concentration (P  < 
0.05) (Fig. 3B). The slope of the line for the RH4 cells 
(m = 0.72) was 1.6-fold greater than the slope of the line 
for the 2008 cells. However, at each Tb 3+ concentration, 
the percent increase in cisplatin accumulation i RH4 cells 
was similar to that in 2008 cells (P > 0.1). Further, the 
revertant RH4 cells were less sensitive to the effects of 
Tb 3+ than the cisplatin-resistant C13" cells (P  < 0.01). 
RH4 cells will require a higher concentration f Tb 3÷ (i.e., 
roughly 280 /zM) to circumvent the defective accumula- 
tion of cisplatin (Fig. 4). 
4. Discussion 
The defective accumulation of cisplatin is an important 
characteristic of cisplatin resistance. We have presented 
evidence that Tb 3+ can influence the transport of cisplatin 
in ovarian cancer cells. Our investigation showed that the 
receptor binding of Tb 3+ can increase the accumulation of
cisplatin in cisplatin-resistant cells. It was demonstrated 
that the cisplatin-resistant cell had more Tb 3+ binding 
sites than the cisplatin-sensitive c ll. The Tb 3+ binding 
protein may thus play a key role in the development 
and/or reversal of cisplatin resistance. 
The mechanism by which cisplatin is transported across 
the plasma membrane is unclear. It is believed that cis- 
platin enters the cell by simple passive diffusion [18]. 
However, there is sufficient evidence to suggest hat a 
specific protein may be involved in the transport of cis- 
platin across the membrane [8,11,19-21]. Diastereoiso- 
meric diaqua(1,2-diphenylethylenediamine)platinum(II) 
sulfates have been shown to have huge differences in their 
cytotoxicities and platinum accumulation i MCF-7 breast 
tumor cells [19]. The cytotoxicity and DNA platination of 
racem ic -d iaq  u a [1  ,2 -b  i s (4 -  
fluorophenyl)ethylenediamine]platinum(II) sulfate were 
considerably greater than that observed for its closely 
related meso-configurated counterpart, meso-diaqua[1,2- 
bis(4-fluorophenyl)ethylenediamine]-platinum(II) s lfate. 
The discrepancy between these two compounds can be 
best explained by a carrier-mediated system. If cisplatin 
enters the cell by simple passive diffusion, then cisplatin 
analogues with similar physicochemical characteristics 
should have similar membrane permeahilities. However, 
this is not true. Stereoisomers of cisplatin, having similar 
hydrophobicities and molecular size, have different rates of 
accumulation. Bednarski [20] did not find a linear relation- 
ship between the hydrophobicity and cytotoxicity of struc- 
turally related analogues of cisplatin, as predicted by a 
passive diffusion model. A carrier-mediated transport sys- 
tem can differentiate between compounds on the basis of 
their structural isomerism. Gately and Howell have sug- 
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gested that the initial rate: of uptake of cisplatin is equally 
divided between passive and carrier-mediated diffusion 
processes [21]. The mediated transport of cisplatin is postu- 
lated to be through a gated channel. 
Calcium channel blockers have been shown to increase 
the cytotoxicity of cispla~fin in some resistant cells [1,22]. 
Onoda et al. have reported that nifedipine, a dihydro- 
pyridine class calcium channel blocker, can synergistically 
enhance the cytotoxicity of cisplatin in murine solid tu- 
mors [23]. The survival cf mice bearing cisplatin-resistant 
tumors and spontaneous pulmonary metastases was in- 
creased significantly by the combination of nifedipine and 
cisplatin. In a subsequent paper, Onoda et al. suggested 
that the cytotoxicity of cisplatin was enhanced by nifedip- 
ine due to their interaction with a specific unidentified 
'target site', in the plasma membrane [22]. This action is 
independent of the inhibitory effect of nifedipine on the 
classical voltage-sensitive Ca2+ channel [1,22]. 
Calmodulin antagonists have been shown to potentiate 
the cytotoxicity of cisplatin in human ovarian carcinoma 
cells, by increasing the cellular uptake of cisplatin [21,24]. 
Kikuchi et al. demonstrated that, in cisplatin-resistant hu- 
man ovarian cancer cells., the cellular uptake of cisplatin 
increased by 1.8-fold in the presence of 5 /zg/ml of the 
calmodulin antagonist W-7 [24]. The stimulatory effects of 
W-7 on the cellular uptake of cisplatin in the cisplatin-re- 
sistant cells were more marked than those on the cellular 
uptake of cisplatin in the parent cisplatin-sensitive c lls 
[24]. Calmodulin is a multipurpose intracellular eceptor 
for Ca 2÷. The Ca2+-calmodulin complex can regulate the 
activity of many membrane transport proteins [25]. 
Our data demonstrates, that the number of the Tb 3+ 
binding sites is increased fin resistant C13" cells. Possibly, 
cisplatin is transported across the plasma membrane via a 
voltage-gated Ca 2+ channel. The voltage-sensitive Ca 2+ 
channel has two Ca 2+ binding sites; site 1 is at the outer 
mouth of the channel and site 2 is located near the inner 
mouth of the channel [8]. The dihydropyridine Ca 2+ chan- 
nel blockers (i.e., organic Ca 2÷ channel blockers) and 
calmodulin antagonists are believe to interact with the 
Ca 2+ channel gate at site 2 of the channel, i.e., the 
cytoplasmic surface of the channel. Site 2 of the Ca 2+ 
channel is a calmodulin-]ike Ca 2÷ binding protein [26]. 
The trivalent lanthanides (i.e., inorganic Ca 2+ channel 
blockers) have been shown to bind to site 1 within the 
channel pore [27]. Lantharfides compete with Ca 2÷ for the 
pore binding site and inhibit the entry of Ca 2+ into the 
cell. The overall mobility of the lanthanides through the 
channel is low, because they bind more tightly to the site 
and have a longer channel exit rate [27]. Cisplatin has been 
shown to behave as a Ca 2-- channel blocker [28]. Cisplatin 
was found to inhibit the depolarization-induced entry of 
Ca 2÷ into isolated cochlear outer hair cells. These results 
imply that cisplatin and terbium may interact with the 
same Ca 2+ binding protein at the level of the plasma 
membrane. 
In some systems, Tb 3+ has been shown to mimic the 
action of Ca 2+ [29]. Like Ca 2+, Tb 3+ suppressed the 
light-evoked response of the neural retina, and hyperpolar- 
ized the membrane potential of horizontal cells in isolated 
fish retina. These effects of Th3+ persisted longer than 
Ca z+, after its removal from the superfusate, because 
Th3+ has the tendency to bind more tightly to Ca 2+ 
binding sites than Ca 2+ [29]. In an earlier paper, we 
reported that Tb 3+ had a biphasic effect on the automatic- 
ity of the rat sinus node [30]. There was an initial tendency 
for the sinus node rate to decrease. This 'early effect', 
which is similar to that observed with La 3+, is probably 
due to the inhibition of the slowly activated Ca2+-depen - 
dent current [31]. Later, the sinus node rate increased 
progressively to reach at 30 min a value 8% above the 
control value. This effect is also similar to the 'late effect' 
of La 3+, which has been explained by an enhanced sar- 
colemmal Ca 2+ influx during the slow diastolic depolar- 
ization, which results in an inward current [32]. 
It is unlikely that our observations in this report are due 
to Tb 3+ blockade of the Ca 2÷ channel. The receptor 
binding of Th3+ may have increased the affinity of cis- 
platin for its transporter. In rat dorsal root ganglion neu- 
rons, Tb 3+ has been shown to increase the GABA-induced 
inward chloride current by prolonging the apparent mean 
open time of single channels [33]. It was suggested that 
Tb 3÷ binds to a distinct allosteric site on the GABA 
receptor-channel complex, so as to increase the affinity of 
GABA for the GABA binding site, and/or to stabilize the 
frequency of occurrence of longer open states. Interaction 
of Tb 3+ with other ion channels that might affect the 
cellular accumulation of cisplatin is therefore possible. 
The biochemical and biophysical properties of the Tb 3 ÷ 
binding protein must be ascertained before any meaningful 
interpretation about its role in cisplatin resistance can be 
made. Cellular accumulation of cisplatin can be regulated 
by the receptor binding of Tb 3+, but only in those C13 * 
cells which overexpressed the Tb 3÷ binding protein [8]. 
Our data suggest hat the terbium-binding protein is not 
associated with the defective accumulation of cisplatin, 
due to the discordant results in the RH4 cells. Even though 
both the RH4 and the C13" cells exhibited identical 
cisplatin accumulation defects. The number of Tb 3+ bind- 
ing sites in resistant C13 * cells was significantly greater 
than that in revertant RH4 cells. The number of Th3+ 
binding sites in revertant RH4 cells was equivalent to the 
number of Tb 3+ binding sites in sensitive 2008 cells. The 
Tb3+-induced enhancement of cisplatin accumulation in 
RH4 cells was about the same as that in 2008 cells. In 
contrast, the degree of enhancement of cisplatin accumula- 
tion by Tb 3+ in C13" cells was significantly greater than 
the degree of enhancement in 2008 cells. The RH4 and 
C13 * cells are approximately 2-fold and 15-fold resistant 
to cisplatin, respectively. It is possible that the terbium-bi- 
nding protein is dependent on the degree of cisplatin 
resistance, and the degree of enhancement of cisplatin 
30 R.G. Canada et al. / Biochimica et Biophysica Acta 1267 (1995) 25-30 
accumulation by Tb 3+ is dependent on the number of 
Tb 3+ binding sites. A complete characterization of the 
Tb 3+ receptor interactions of cisplatin may prove neces- 
sary to fully understand the molecular events involved in 
its cytotoxicity. This knowledge may eventually afford us 
the opportunity to improve the efficacy of cisplatin in the 
treatment of ovarian cancer. 
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